TrialStudy to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions
Trial details
- Registry ID
- NCT05592418
- Phase
- Phase 2
Drug research
Rintatolimod
Open a linked trial to see its study details and recorded changes, or check the regulatory events below and follow their sources.
Drug identity checked against registry records
Also recorded as Ampligen; Rintatolimod (poly I : poly C12U); poly I : poly C12U
A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.
Included trials
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID ConditionsNCT05592418 | AIM | Phase 2 | Completed | 2023-11-17Actual |
| Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPCNCT05494697 | AIM | Phase 2 | Suspended | 2031-02Estimated |
Ampligen Combined With SOC Versus SOC Alone Following First-Line Therapy in Subjects With LAPC
Trial details
- Registry ID
- NCT05494697
- Phase
- Phase 2
Regulatory dates and decisions
| No regulatory events match this view.Try another date range or view. Events appear after automated source checks. This does not mean no FDA events have occurred. Dates that a source does not disclose stay undisclosed. |